OOIR: Observatory of International Research

Papers

(The median citation count of Hematological Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
324 \| RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA	38
580 \| CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF HIGH‐GRADE B‐CELL LYMPHOMAS TRANSFORMED FROM INDOLENT LYMPHOMAS IN HIV‐NEGATIVE AND HIV‐POSITIVE PATIENTS	37
522 \| CLINICAL APPROACH AND OUTCOME OF DIFFUSE LARGE B CELL LYMPHOMA WITH PERSISTENT PET POSITIVITY AFTER FRONTLINE TREATMENT: SUBGROUP ANALYSIS OF THE STRIDER STUDY	36
546 \| PATIENT REPORTED OUTCOMES AND PREDICTORS OF INHIBITOR USE IN CHRONIC LYMPHOCYTIC LEUKEMIA—AN ANALYSIS OF THE LYMPHOMA COALITION’S 2024 GLOBAL PATIENT SURVEY	34
617 \| INCIDENCE AND SURVIVAL OF MANTLE CELL LYMPHOMA IN ENGLAND 2014–2021: A NATIONAL COHORT STUDY FROM THE UNCOVER STUDY GROUP	33
825 \| MEASURING SYMPTOM IMPROVEMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: EMERGING RESULTS FROM AN INCLUSIVE, ITERATIVE PROCESS	30
613 \| LIMITED‐STAGE MANTLE CELL LYMPHOMA: CLINICAL FEATURES, MANAGEMENT, AND OUTCOMES IN A MULTICENTER RETROSPECTIVE STUDY FROM SPAIN	28
161 \| OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM	27
801 \| AS A NOVEL EPIGENETIC MODULATOR, EZH1/2 DUAL INHIBITOR HM97662 EXHIBITS ANTITUMOR EFFICACY IN HEMATOLOGICAL MALIGNANCIES AND OVERCOMES EZH2‐INHIBITOR MEDIATED RESISTANCE	26
514 \| CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?	24
439 \| ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	24
490 \| MOLECULAR LANDSCAPE OF DISTINCT FOLLICULAR LYMPHOMA HISTOLOGIC GRADES: INSIGHTS FROM GENOMIC AND TRANSCRIPTOME ANALYSES	23
407 \| RADIATION THERAPY FOR OLIGO‐RELAPSED/PROGRESSIVE DISEASE POST‐STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA: FACTORS ASSOCIATED WITH FAVORABLE OUTCOMES	22
361 \| REAL‐WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE	21
660 \| IMPACT OF HEALTHCARE SETTING ON DIFFUSE LARGE B‐CELL LYMPHOMA OUTCOMES—A REAL‐WORLD COMPARATIVE STUDY	21
	20
295 \| EARLY MORTALITY DLBCL PREDICTION WITH AN ENHANCED R‐IPI SCORE DEVELOPED USING AN ENSEMBLE MACHINE LEARNING MODEL	19
639 \| DIFFUSE LARGE B CELL LYMPHOMA: A TUNISIAN MULTICENTER EXPERIENCE	19
372 \| DECODING THE CD4+T CELL‐ HODGKIN REED‐STERNBERG CELL CROSSTALK: HOW TO CUT THE ACHILLES' HEEL OF PEDIATRIC HODGKIN LYMPHOMA?	19
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS	18
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK	18
	18
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA	18
290 \| REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY	18
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)	17

QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERS	17
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)	17
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models	17
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma	17
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY	16
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma	15
EFFICACY OF FRONT‐LINE IMMUNOCHEMOTHERAPY FOR TRANSPLANT‐INELIGIBLE MANTLE CELL LYMPHOMA: A NETWORK META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	15
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)	15
MINIMAL RESIDUAL DISEASE STATUS IMPROVED THE RESPONSE EVALUATION IN PATIENTS WITH WALDENSTRöM’S MACROGLOBULINEMIA	14
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–2022	14
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma	14
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders	14
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS	14
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study	13
216 \| EPCORITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL‐1	13
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis	13
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma	13
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model	12
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis	12
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial	12
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma	12
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax	12
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions	12
Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis	11
How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia	11
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects	11
A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐2	11
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma	11
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime	11
240 \| EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	11
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma	11
Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1	11
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	11
Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma	11
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016	11
Clonal Hematopoiesis: Impact on Health and Disease	11
Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting	10
Issue Information	10
EFFICACY AND SAFETY OF BTK INHIBITORS IN VITREORETINAL LYMPHOMA: A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF 24 PATIENTS	10
Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience	10
MR‐GUIDED ADAPTIVE RADIOTHERAPY FOR GASTRIC LYMPHOMA, PRELIMINARY RESULTS FROM ONGOING STUDY	10
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)	10
Issue Information	10
Remote Monitoring of CAR T‐Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program	10
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study	10
Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience	10
IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE	9
Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non‐H.pylori Helicobacter using multiplex PCR: a retrospective analysis	9
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvement	9
CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC ACCURACY AND REFINE CELL‐OF‐ORIGIN CLASSIFICATION OF MATURE T‐CELL LYMPHOMAS	9

Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study	9
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL	9
LYMPHOMA TISSUE EXPLANTS TO ANTICIPATE RESPONSE TO TARGETED THERAPIES	9
PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA	9
A PREDICTIVE MODEL FOR ULTRA‐HIGH RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE‐CENTER STUDY IN CHINA	9
BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLANT‐ASSOCIATED LYMPHOMA (BIA‐ALCL) IN WOMEN WITH BREAST CANCER RECONSTRUCTED WITH TEXTURED BREAST IMPLANTS	9
TUESDAY, 13 JUNE 2023 FROM 16:30 TO 18:00 CEST (ROOM B2)	9
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study	9
INVESTIGATING THE SAFETY AND EFFICACY OF IV FENTANYL FOR BROWN FAT MITIGATION IN ¹⁸FDG‐PET/CT IN PEDIATRIC ONCOLOGY: A MULTI‐INSTITUTIONAL EXPERIENCE	9
ELUCIDATING THE MOLECULAR MECHANISMS OF CLONAL EVOLUTION IN MULTIPLE MYELOMA THROUGH SINGLE‐CELL RNA SEQUENCING	9
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA	9
Deregulated hsa‐miR‐23a‐3p and hsa‐mir‐148a‐3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesis	9
EPIGENETIC REGULATION OF IMMUNE MICROENVIRONMENT INTERACTIONS IN LYMPHOMA	9
830 \| A PHASE 1 STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV‐291, A CD79B‐TARGETING ADC IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA	8
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)	8
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib	8
192 \| FOLLICULAR LYMPHOMA DISPLAYS DISTINCT GENE EXPRESSION PROFILES ACCORDING TO HISTOLOGICAL GRADE	8
456 \| IDENTIFICATION OF AN OPTIMAL ABSOLUTE LYMPHOCYTE COUNT BEFORE LEUKAPHERESIS IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CART	8
758 \| CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEPATOSPLENIC T‐CELL LYMPHOMA	8
40 \| THE DIRECT STUDY: A ROADMAP FOR ctDNA‐BASED RISK PREDICTION, MOLECULAR PROFILING AND MRD DETECTION IN DIFFUSE LARGE B CELL LYMPHOMA	8
855 \| A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE	8
79 \| OUTCOME OF AUTOLOGOUS AND ALLOGENIC HCT IN BURKITT LYMPHOMA: AN EBMT REGISTRY ANALYSIS	8
538 \| IGVH MUTATIONAL STATUS AS A PROGNOSTIC FACTOR AFFECTING RELAPSE‐FREE SURVIVAL AND TREATMENT‐FREE INTERVAL IN CLL PATIENTS: SINGLE‐CENTER EXPERIENCE WITH 110 CASES	8
202 \| IMMUNOSURVEILLANCE OF PRECANCEROUS GERMINAL CENTER B CELLS	8
876 \| LYMPHOMA‐ASSOCIATED BONE MARROW HEMOPHAGOCYTOSIS: A RETROSPECTIVE, SINGLE‐CENTER STUDY OF 67 PATIENTS	8
57 \| CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL	8
197 \| CD4+ T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP	8
863 \| RADIOTHERAPY IN PREGNANT PATIENTS WITH HODGKIN’S LYMPHOMA: CLINICAL OUTCOMES AND DOSIMETRIC ASSESSMENT	8
802 \| A STUDY ON THE MECHANISM OF THE NOVEL HIGHLY SELECTIVE HDAC INHIBITOR PURINOSTAT MESYLATE IN DOUBLE‐HIT LYMPHOMA AND ITS THERAPEUTIC POTENTIAL COMBINATION WITH VENETOCLAX	8
515 \| PREDICTIVE VALUE OF INTERIM AND END OF TREATMENT PET/CT IN FRONT‐LINE TREATMENT OF PERIPHERAL T‐CELL LYMPHOMA	8
263 \| LONG‐TERM OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS WHO DISCONTINUE BRUTON TYROSINE KINASE INHIBITOR THERAPY	8
363 \| REAL‐WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: 2‐YEAR FOLLOW‐UP FROM THE GATLA STUDY	8
672 \| REAL‐WORLD DATA OF LISOCABTAGENE MARALEUCEL AS SECOND LINE THERAPY FOR PATIENTS WITH LARGE B‐CELL LYMPHOMA: FIRST RESULTS OF THE FRENCH DESCAR‐T REGISTRY BY LYSA	8
Ultrasonography‐guided core‐needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front‐line biopsies in a multicenter Italian study	7
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma	7
Promising clinical efficacy and acceptable safety profile of sequential P‐GEMOX and radiotherapy for localized ENKTL	7
Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma	7
510 \| THE ANTIBODY‐DEPENDENT CELLULAR CYTOTOXICITY AND METABOLIC TUMOR VOLUME BALANCE: A NOVEL PREDICTIVE MARKER FOR TUMOR RECURRENCE IN DIFFUSE LARGE B‐CELL LYMPHOMA	7
FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia	7
Post‐transplant lymphoproliferative disease in children, adolescents, and young adults	7
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational study	7
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis	7
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center	7
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDY	7
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies	7
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY	7
Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti‐CD19 chimeric antigen receptor T‐cell	7
512 \| PROGNOSTIC VALUE OF BASELINE METABOLIC BIOMARKERS ASSESSED BY F18‐FDG PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA	7
COMBINING BASELINE TOTAL METABOLIC TUMOR VOLUME AND BETA‐2‐MICROGLOBULIN LEVELS PREDICTS OUTCOMES IN HIGH BURDEN FOLLICULAR LYMPHOMA	7
115 \| THE BTK DEGRADER BGB‐16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI‐TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS	6
COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation	6
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy	6
588 \| SHORT‐COURSE IMMUNOCHEMOTHERAPY FOLLOWED BY SEQUENTIAL ORELABRUTINIB IN PATIENTS WITH HIGH‐RISK MARGINAL ZONE LYMPHOMA	6
785 \| HEMATOLOGIC TOXICITY ANALYSIS OF CAR‐T CELL THERAPY: A RETROSPECTIVE REAL‐WORLD STUDY	6
859 \| NOVEL APPLICATION OF DEEP‐LEARNING BASED MRI FOR DETECTION, SEGMENTATION, AND RADIOTHERAPY RESPONSE ASSESSMENT IN PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA	6
169 \| PHOSPHO‐STAT3 EXPRESSION AND JAK/STAT PATHWAY ACTIVATION ACROSS GENETIC SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA	6
Issue Information	6
A REAL‐WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA IN CHINA	6
873 \| DISPARITIES IN LYMPHOMA TREATMENT ACCESS AT RIAU, ONE OF PROVINCE IN INDONESIA: WHEN LATE DIAGNOSIS AND UNEQUAL CARE DEFINE OUTCOMES	6
OT04 \| GOLSEEK‐1: A PHASE 3, DOUBLE‐BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R‐CHOP VERSUS PLACEBO + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK, LARGE B‐CELL LYMPHOMA	6
771 \| TREATMENT OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA COMPLICATED BY SEVERE RENAL FAILURE REQUIRING HEMODIALYSIS	6
555 \| ADVERSE EVENTS OF INTEREST WITH ZANUBRUTINIB VERSUS FIXED‐DURATION COMBINATION OF VENETOCLAX + OBINUTUZUMAB IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA	6
Author Index	6
Distinguishing myelodysplastic syndromes with moderate‐to‐severe bone marrow fibrosis from triple‐negative primary myelofibrosis based on clinical and genetic covariates	6
453 \| EFFICACY AND TOXICITY OF RADIATION THERAPY PRIOR TO CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	6
537 \| CLINICAL CHARACTERISTICS OF HEPATITIS B VIRUS REACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB: A RETROSPECTIVE MULTICENTRIC STUDY	6
768 \| EFFICACY AND SAFETY OF SELINEXOR‐MELPHALAN COMBINED CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA	6
534 \| EFFICACY OF BTK INHIBITOR‐BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA—A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META‐ANALYSIS	6
634 \| OPTIMAL TREATMENT FOR DOUBLE‐EXPRESSOR LYMPHOMA IN THE ERA OF NOVEL AGENTS: A SYSTEMATIC REVIEW AND META‐ANALYSIS	6
Phase 2 study to investigate the efficacy and safety of IMC‐001, anti‐PD‐L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study	5
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study	5
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition	5
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMA	5
Metabolic reprograming of exhausted intratumoral CD8+ T‐cell underlies anti‐tumor activity of SUMOylation inhibitors in Large B Cell Lymphoma	5
219 \| PATIENT REPORTED OUTCOMES FROM BRUIN CLL‐321: PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKi PRETREATED CLL/SLL	5
742 \| OUTCOME OF PATIENTS WITH T‐CELL/HISTIOCYTE‐RICH LARGE B‐CELL LYMPHOMA: A SINGLE INSTITUTION SERIES	5
269 \| REAL‐WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH TREATMENT‐NAIVE MANTLE CELL LYMPHOMA IN THE UK, SWEDEN, AND FRANCE	5
KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	5
POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA	5
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHL	5

DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A FEASIBILITY STUDY OF THE AIDS MALIGNANCY CONSORTIUM (AMC 105)	5
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.	5
PHASE‐2 FIRST‐IN‐INDIA INDUSTRY STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN‐003A) IN RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY B‐NHL SUBANALYSIS	5
Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients	5
619 \| IMPACT OF ASCT CONSOLIDATION AND RITUXIMAB MAINTENANCE ON SURVIVAL IN REAL‐WORLD PATIENTS WITH MANTLE CELL LYMPHOMA IN SPAIN. THE GELTAMO‐MCL‐2022 STUDY	5
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0	5
847 \| PALT TRIAL: FIRST IN CLASS GLYCO‐HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA	5
236 \| MOSUNETUZUMAB DEMONSTRATES DURABLE CLINICAL BENEFIT IN PATIENTS WITH COMPLETE RESPONSE AND HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	5
508 \| BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL	5
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R‐CHOP‐LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON‐GCB DLBCL	5
Genomic abnormalities involving class I HLA are common in advanced cutaneous T‐cell lymphoma	5
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents	5
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI)	5
THE ROLE OF CD5+ AS AGGRESSIVE BIOMARKER IN DIFFUSE LARGE B‐CELL LYMPHOMA	5
REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL	5
PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS	5
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect	5
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma	5
The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia	5
33 \| GLOFITAMAB PLUS R‐ICE OR AS MONOTHERAPY IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: UPDATED ANALYSIS FROM THE iMATRIX‐GLO STUDY	5
179 \| GENOMIC AND TRANSCRIPTIONAL SINGLE‐CELL HETEROGENEITY IN GERMINAL‐CENTER LYMPHOMAS: INSIGHTS INTO FOLLICULAR LYMPHOMA TRANSFORMATION	5
850 \| GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA	5
A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD courses	5
Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cells	5
PERIPHERAL T CELL LYMPHOMA (PTCL) AND TREATMENT OUT‐COME SINGLE CENTRE RETROSPECTIVE STUDY	5
Combined single‐cell and spatially‐resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organization	5
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerability	5
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis	5
LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL‐IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA	4
Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas	4
Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment	4
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs	4
PROGNOSTIC SIGNIFICANCE OF A NOVEL AMINO ACID METABOLIC INDEX IN CHRONIC LYMPHOCYTIC LEUKEMIA	4
630 \| POLATUZUMAB VEDOTIN‐BASED COMBINATION THERAPY DEMONSTRATES EFFICACY AND SAFETY IN ELDERLY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS	4
215 \| DISCONTINUATION OF BTK INHIBITOR MONOTHERAPY IN CLL PATIENTS WITHOUT DISEASE PROGRESSION: A REAL‐WORLD STUDY FROM THE SPANISH CLL GROUP (GELLC)	4
385 \| THE PROGNOSTIC ROLE OF WHOLE BLOOD EPSTEIN‐BARR VIRUS DNA LOAD IN ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA	4
345 \| PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: A MULTICENTRIC OBSERVATIONAL STUDY OF SPANISH LYMPHOMA GROUP GELTAMO	4
COMBINED MODALITY ULTRA‐LOW‐DOSE ADAPTIVE RADIOTHERAPY AND RITUXIMAB AS TREATMENT STRATEGY FOR INDOLENT NON‐HODGKIN LYMPHOMAS: THE UT SOUTHWESTERN EXPERIENCE	4
Treatment intensification might not improve survival in high‐grade B‐cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled a	4
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study	4
The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis	4
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL	4
Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas	4
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas	4
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL	4
COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS	4
Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocation	4
214 \| FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE	4
884 \| THE EMOTIONAL BURDEN OF LYMPHOMA: HOW LYMPHOMA SURVIVORS PERCEIVE RELATIONSHIPS AND SELF‐IMAGE	4
326 \| GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS	4
Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma	4
Deciphering the role of MSI2 as a regulator of stem‐like properties in mantle cell lymphoma	4
824 \| R‐CHOP WITH SINTILIZUMAB IN FIRST‐LINE TREATMENT OF LARGE B‐CELL LYMPHOMA PATIENTS WITH TP53 MUTATIONS AND PD‐L1 EXPRESSION: A RANDOMIZED, MULTICENTER CLINICAL STUDY	4
STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response	4
What drives pediatric Burkitt lymphoma? Timing events in the evolution of cancer using single‐cell whole genome sequencing	4
MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMA	4
49 \| COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA	4
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment	4
PROTEOMIC PROFILING IDENTIFIES GRANZYME B INHIBITOR SERPIN B9 AS MEDIATOR OF RESISTANCE TO CAR T‐CELL AND BISPECIFIC ANTIBODY TREATMENT IN NODAL B‐CELL LYMPHOMA	4
466 \| CAR‐T THERAPY WITH OX40 SIGNALING DRIVES CLONAL EXPANSION OF CD4+ T CELLS AND OVERCOMES IMMUNOSUPPRESSIVE MICROENVIRONMENT IN B‐CELL LYMPHOMA: A PHASE I TRIAL	4
374 \| IMAGING PITFALLS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SEARCH FOR CAYAHL INITIATIVE TO BRIDGE MULTIDISCIPLINARY PATIENT CARE	4
849 \| INTERIM PET‐ADAPTED DE‐ESCALATION CHEMOTHERAPY REGIMEN FOR ADVANCED STAGE cHL USING BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, DOXORUBICIN, AND DACARBAZINE	4
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report	4
UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST‐BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS	4
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia	4
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial	3
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial	3
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY	3
287 \| SHORT‐TERM DOSE‐DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV‐ AND HIV+ PATIENTS WITH BURKITT LYMHOMA	3
222 \| EXPLORATION OF SURROGATE MARKERS FOR EZH2 Y646 MUTATION IN FOLLICULAR LYMPHOMA: COMPARATIVE STUDY INCLUDING MATCHED PAIR SAMPLES	3
PROGNOSTIC VALUE OF METABOLIC PARAMETERS OF BASELINE PET/CT IN PATIENTS WITH DOUBLE EXPRESSION TYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA	3
Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation	3
Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe	3
CIRCULATING TUMOR DNA (LIQUID BIOPSY)	3
139 \| ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA	3
The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)	3
Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profiles	3
Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study	3
10 \| THE ROLE OF ARTIFICIAL INTELLIGENCE IN CLINICAL TRIAL DESIGN AND ANALYSIS	3
463 \| ANTI‐CD19 CAR‐T CELL THERAPY IN RELAPSED/REFRACTORY T‐CELL/HISTIOCYTE‐RICH LARGE B‐CELL LYMPHOMA: INSIGHTS FROM THE FRENCH DESCAR‐T REGISTRY, A LYSA STUDY	3
First line therapy of CLL	3
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL‐WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP.	3
Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first‐line immunochemotherapy: a real‐world prospective study	3
Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse	3
11 \| PREDICTING 2‐YEAR TIME TO PROGRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING ARTIFICIAL INTELLIGENCE ON WHOLE‐BODY PET SCANS	3
LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY	3
THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTACI ERADICATION WITH A SIX‐MONTH REGIMEN OF DOXYCYCLINE IN PATIENTS WITH STAGE‐I MALT LYMPHOMA OF THE OCULAR ADNEXAE	3
Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma	3
254 \| RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY	3
MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 Inhibitors in ibrutinib resistance mantle cell lymphoma	3
Cellular therapy in lymphoma	3
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT	3
	3
P+R‐ICE: PEMBROLIZUMAB IN COMBINATION WITH R‐ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ‐ ONGOING TRIAL	3
443 \| A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS	3